JPM 2022: New Johnson & Johnson CEO Duato points out 5 pipeline meds that can generate $5B+

Johnson & Johnson, preparing for a consumer health spinoff late next year, has big plans in pharmaceuticals for the coming decade.

By 2025, the company aims to generate $60 billion in pharma sales, leaning mostly on existing medicines for growth until then, new CEO Joaquin Duato said during the virtual J.P. Morgan Healthcare Conference on Monday. In the second half of the decade, the company expects a handful of new launches to contribute in a major way.